0.0233929157257 seconds

Nattokinase and Cholesterol

Population: 82 patients with hyperlipidemia

Intervention: Nattokinase 2,000 FU/day for 26 weeks

Findings: Significant reductions in total cholesterol, LDL, and triglycerides, with modest increases in HDL.

Reference: Ren, S. et al. Clin Appl Thromb Hemost. 2017;23(8):958–965.

Population: 45 subjects with cardiovascular risk factors

Intervention: Nattokinase 6,000 FU/day for 2 months

Findings: Lowered total cholesterol and LDL, improved blood pressure and fibrinolytic activity.

Reference: Huang, Y. et al. Nutr Res. 2009;29(3):190–196.

Population: 546 participants across 6 randomized controlled trials

Findings: Nattokinase supplementation showed reductions in blood pressure and some lipid improvements, though cholesterol effects were dose-dependent and inconsistent.

Reference: Li, X. et al. Rev Cardiovasc Med. 2023;24(8):234.
Link

Summary: Reviews clinical and mechanistic evidence that nattokinase can activate lipases, inhibit HMG-CoA reductase, and reduce atherosclerotic plaque area in human studies.

Reference: Wei, C. et al. Nutrients. 2025;17(11):1784.
Link

Population: Adults with mild atherosclerosis and hyperlipidemia

Intervention: High-dose nattokinase (10,800 FU/day) for 12 months

Findings: LDL and triglycerides decreased significantly, and carotid plaque size reduced by ~36%.

Reference: Reported in NAD.com summary of trial (2025).
Link